You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: R

    DESCRIPTION Based on the prevailing evidence we believe that a highly effective vaccine for HIV prophylaxis must induce long lasting broadly cross reactive antibody responses to envelope that exhibit antiviral activity as well as multi antigen polyfunctional CD and CD T cell responses that produce antiviral chemokines and cytokines and are possibly biased towards an effector memory phenot ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A simple assay system for rapid detection of circulating tumor cells

    SBC: TELOVISION, LLC            Topic: NCI

    DESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Subcutaneous Drug Development for Portal Hypertension Ascites

    SBC: PHARMAIN CORPORATION            Topic: 300

    DESCRIPTION provided by applicant The prevalence of all types of ascites irrespective of the cause is in with of these due to cirrhosis Ascites is treated with a salt restricted diet and pharmacologic therapy using diuretics However in to of patients with ascites the ascites becomes refractory to medical therapy Half of patients who develop refractory ascites due ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Staphylococcus aureus is a Gram positive human pathogen that causes a wide range of infections from skin and soft tissue infections SSTI to life threatening sepsis and pneumonia The pathogenicity of S aureus is dependent on numerous virulence factors including cell surface proteins and polysaccharides as well as secreted toxins An important group of thes ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Automating mosquito microdissection for a malaria PfSPZ vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION Malaria causes andgt million clinical cases and million deaths annually is responsible for andgt loss of GDP in Africa and is a serious concern for travelers and military personnel A highly effective vaccine is desperately needed and radiation attenuated Plasmodium falciparum Pf sporozoites SPZ and non attenuated PfSPZ with chloroquine chemoprophylaxis ChemoProphylax ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Medical countermeasure after radiation exposure

    SBC: PHARMAIN CORPORATION            Topic: NIAID

    DESCRIPTION provided by applicant New treatments for radiation injury to the GI tract are desperately needed to ensure survival after exposure to ionizing radiation arising from accident nuclear warfare or terrorist attacks dirty bombs Radiation injuries to the hematopoietic system and the GI tract are fatal with the latter more acutely fatal No treatment is available fo the more acute l ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD

    SBC: Asclepix Therapeutics, Inc.            Topic: N

    DESCRIPTION provided by applicant Long term anti angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B Pandey Ph D PI Aleksander S Popel Ph D Co I Jordan J Green Ph D Co I Peter A Campochiaro M D Co I of subaward Project Summary Current therapies for wet age related macular degeneration AMD target vascular endothelial growth factors VEGFA and pla ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Reproducibility Assessment for Multivariate Assays

    SBC: INSILICOS            Topic: 400

    DESCRIPTION provided by applicant This Small Business Innovation Research project addresses the problem of assessing reproducibility in analyzing high throughput data In feature selection for data with large numbers of features it is well known that some features will appear to affect an outcome by chance and that subsequent predictions based on these features may not be as successful as ini ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Topical Silver Sulfadiazine Formulations with Improved Efficacy and Toxicity Prof

    SBC: Novion Technologies            Topic: 300

    DESCRIPTION provided by applicant Silver Sulfadiazine SSD is the most widely used topical antimicrobial agent in the world and while effective against a wide variety of pathogens i has been shown to delay wound healing Formulation of SSD into creams and gels with the inclusion of a naturally occurring component additive has been shown to significantly lower the toxicity of the formulation ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government